Shares of CureVac N.V. (NASDAQ:CVAC - Get Free Report) were down 0.1% during mid-day trading on Friday . The company traded as low as $5.38 and last traded at $5.40. Approximately 751,012 shares traded hands during trading, a decline of 4% from the average daily volume of 786,138 shares. The stock had previously closed at $5.40.
Wall Street Analyst Weigh In
A number of research firms have recently commented on CVAC. Citizens Jmp downgraded CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. Citigroup lowered shares of CureVac to a "market perform" rating in a report on Thursday, June 12th. UBS Group downgraded shares of CureVac from a "strong-buy" rating to a "neutral" rating and decreased their price objective for the stock from $12.00 to $5.50 in a research note on Thursday, June 26th. Jefferies Financial Group reissued a "hold" rating and issued a $5.00 target price (down previously from $7.00) on shares of CureVac in a research note on Friday, June 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $10.00 price target on shares of CureVac in a research report on Wednesday, May 28th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $6.83.
Read Our Latest Analysis on CureVac
CureVac Price Performance
The company has a market cap of $1.21 billion, a price-to-earnings ratio of 5.88 and a beta of 2.53. The company's 50-day simple moving average is $4.49 and its 200-day simple moving average is $3.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.64.
CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). CureVac had a net margin of 35.44% and a return on equity of 30.89%. The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.27 million. On average, equities research analysts anticipate that CureVac N.V. will post 0.72 EPS for the current year.
Institutional Trading of CureVac
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC grew its stake in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after purchasing an additional 3,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of CureVac by 14.3% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company's stock worth $81,000 after buying an additional 3,648 shares in the last quarter. Signaturefd LLC grew its position in shares of CureVac by 29.2% during the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company's stock worth $123,000 after buying an additional 8,170 shares in the last quarter. Greenleaf Trust bought a new stake in shares of CureVac in the first quarter worth $31,000. Finally, XTX Topco Ltd raised its holdings in CureVac by 90.2% in the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock valued at $83,000 after acquiring an additional 11,553 shares in the last quarter. 17.26% of the stock is owned by hedge funds and other institutional investors.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.